KD Logo

Anavex Life Sciences Corporation’s latest rating changes from various analysts

Anavex Life Sciences Corporation’s recent filing unveils that its Director Donhauser Peter D.O. acquired Company’s shares for reported $10319.0 on Jun 14 ’24. In the deal valued at $3.64 per share,2,835 shares were bought. As a result of this transaction, Donhauser Peter D.O. now holds 5,000 shares worth roughly $31500.0.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Thomas Steffen bought 5,000 shares, generating $22,600 in total proceeds. Upon buying the shares at $4.52, the Director now owns 5,000 shares.

Before that, MISSLING CHRISTOPHER U sold 73,380 shares. Anavex Life Sciences Corporation shares valued at $374,972 were divested by the President and CEO at a price of $5.11 per share. As a result of the transaction, MISSLING CHRISTOPHER U now holds 1,250,210 shares, worth roughly $7.88 million.

Cantor Fitzgerald downgraded its Anavex Life Sciences Corporation [AVXL] rating to a Neutral from a an Overweight in a research note published on December 06, 2022; the price target was decreased to $11 from $16. A number of analysts have revised their coverage, including Berenberg’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. BTIG Research began covering AVXL with “Buy” recommendation on September 23, 2021. H.C. Wainwright maintained its rating on December 16, 2020. It rated AVXL as “a Buy”.

Price Performance Review of AVXL

On Friday, Anavex Life Sciences Corporation [NASDAQ:AVXL] saw its stock fall -5.05% to $6.30. Over the last five days, the stock has lost -2.93%. Anavex Life Sciences Corporation shares have fallen nearly -32.28% since the year began. Nevertheless, the stocks have fallen -32.71% over the past one year. While a 52-week high of $10.45 was reached on 07/29/24, a 52-week low of $3.25 was recorded on 04/25/24. SMA at 50 days reached $5.01, while 200 days put it at $5.52. A total of 0.65 million shares were traded, compared to the trading of 0.81 million shares in the previous session.

Levels Of Support And Resistance For AVXL Stock

The 24-hour chart illustrates a support level at 6.12, which if violated will result in even more drops to 5.93. On the upside, there is a resistance level at 6.60. A further resistance level may holdings at 6.89. The Relative Strength Index (RSI) on the 14-day chart is 54.58, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.90%. Stochastics%K at 39.53% indicates the stock is a holding.

The most recent change occurred on September 28, 2020 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $12 price target.

Most Popular